Publications and communications of Evelyne WILLEMS

Voisot, A., Triffaux, F., Roland, I., Meex, C., Detrembleur, N., Baron, F., WILLEMS, E., WALTREGNY, D., Beguin, Y., & Servais, S. (22 September 2023). Endovesical instillation of Cidofovir in the treatment of BK polyomavirus hemorrhagic cystitis after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 71 (1), 103366. doi:10.1016/j.retram.2022.103366

Bayoudh, F., Giot, J.-B., Descy, J., Fontaine, C., Hayette, M.-P., Baron, F., WILLEMS, E., Beguin, Y., FRIPPIAT, F., & Servais, S. (2023). Oral minocycline as systemic therapy for uncomplicated venous access device-related bloodstream infection with coagulase-negative staphylococci after allogeneic hematopoietic cell transplantation. Current Research in Translational Medicine, 72 (1), 103422. doi:10.1016/j.retram.2023.103422

De Voeght, A., WILLEMS, E., Servais, S., Seidel, L., Pirotte, M., Massion, P., Layios, N., Pereira, M., Misset, B., CANIVET, J.-L., Beguin, Y., & Baron, F. (31 August 2022). Overall Survival Rate in Allogeneic Stem Cell Transplanted Patients Requiring Intensive Care Can Be Predicted by the Prognostic Index for Critically Ill Allogeneic Transplantation Patients (PICAT) and the Sequential Organ Failure Assessment (SOFA) Scores. Cancers, 14 (17), 4266. doi:10.3390/cancers14174266

BARZIN, A., Geurten, C., WILLEMS, E., Baron, F., Beguin, Y., & Servais, S. (May 2022). Maladie du greffon contre l’hôte aiguë et chronique après allogreffe de cellules souches hématopoïétiques. Revue Médicale de Liège, 77 (5-6), 345 - 353.

Canti, L., Ariën, K. K., Desombere, I., Humblet-Baron, S., Pannus, P., Heyndrickx, L., HENRY, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., SEIDEL, L., Michiels, J., Willems, B., Goossens, M. E., Beguin, Y., Marchant, A., & Baron, F. (11 April 2022). Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients. Cancer Cell, 40 (4), 335-337. doi:10.1016/j.ccell.2022.02.005

GREGOIRE, C., SERVAIS, S., WILLEMS, E., BAUDOUX, E., LECHANTEUR, C., BRIQUET, A., Bettonville, V., DETRY, O., ERPICUM, P., JOURET, F., LOUIS, E., BARON, F., & BEGUIN, Y. (April 2022). Immunothérapie cellulaire au CHU de Liège : avancées, défis et perspectives. Revue Médicale de Liège, 77 (4), 206-211.

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3
* These authors have contributed equally to this work.

Ehx, G.* , Ritacco, C.* , HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505
* These authors have contributed equally to this work.

Ingels, J., De Smet, S., Heyns, K., Lootens, N., Segaert, J., Taghon, T., Leclercq, G., Vermaelen, K., WILLEMS, E., BAUDOUX, E., Kerre, T., Baron, F., & Vandekerckhove, B. (2021). Treatment of a patient with severe cytomegalovirus (CMV) infection after haploidentical stem cell transplantation with donor-derived CMV-specific T cells. Acta Clinica Belgica: International Journal of Clinical and Laboratory Medicine, 76, 482-486. doi:10.1080/17843286.2020.1752446

MAQUET, C., BEGUIN, Y., DE PRIJCK, B., WILLEMS, E., SERVAIS, S., & BONNET, C. (2021). Le lymphome diffus à grandes cellules B : nouveau traitement révolutionnaire par des cellules immunitaires génétiquement modifiées appelées «CAR T cells». Revue Médicale de Liège, 76, 476-481.

Narinx, J., SERVAIS, S., BARON, F., BEGUIN, Y., & WILLEMS, E. (2021). Allogreffes de cellules souches hématopoïétiques : principes généraux et progrès récents. Revue Médicale de Liège, 76, 464-469.

Ritacco, C.* , Ehx, G.* , GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0
* These authors have contributed equally to this work.

Antoine-Poirel, H., Vanspauwen, M., Macq, G., De Geyndt, A., Maertens, J., WILLEMS, E., Selleslag, D., Poiré, X., Theunissen, K., Graux, C., Kerre, T., Zachée, P., Meuleman, N., De Becker, A., Verlinden, A., Van Obbergh, F., Schuermans, C., De Wilde, V., JASPERS, A., ... Beguin, Y. (2019). Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres. Bone Marrow Transplantation, 54, 1434-1442. doi:10.1038/s41409-019-0458-8

Fossard, G., Broussais, F., Coelho, I., Bailly, S., Nicolas-Virelizier, E., Toussaint, E., Lancesseur, C., Le Bras, F., WILLEMS, E., Tchernonog, E., Chalopin, T., Delarue, R., Gressin, R., Chauchet, A., Gyan, E., Cartron, G., Bonnet, C., BOUABDALLAH, R., SALLES, G., & BACHY, E. (2018). Role of up-front autologous stem cell transplantation in peripheral T-cell lymphoma for patients in response after induction: An analysis of patients from LYSA centers. Annals of Oncology, 29, 715-723. doi:10.1093/annonc/mdx787

Pirotte, M.* , Forte, F.* , Lutteri, L., WILLEMS, E., DURAN, U., Belle, L., Baron, F., BEGUIN, Y., Maquet, P., BODART, O.* , & Servais, S.*. (2018). Neuronal surface antibody-mediated encephalopathy as manifestation of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Journal of Neuroimmunology, 323, 115-118. doi:10.1016/j.jneuroim.2018.08.003
* These authors have contributed equally to this work.

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Grégoire, C., GUIOT, J., Vertenoeil, G., WILLEMS, E., HAFRAOUI, K., CORHAY, J.-L., LOUIS, R., & BEGUIN, Y. (February 2016). Yellow nail syndrome after allogeneic haematopoietic stem cell transplantation in two patients with multiple myeloma. Acta Clinica Belgica, 71, 428-430. doi:10.1080/17843286.2015.1122872

SERVAIS, S., GREGOIRE, C., BARON, F., WILLEMS, E., BRIQUET, A., BAUDOUX, E., DELLOYE, O., GIET, O., LECHANTEUR, C., & BEGUIN, Y. (2016). Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Belgian Journal of Hematology, 7, 229-235.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

Baron, F., Zachée, P., Maertens, J., Kerre, T., ORY, A., SEIDEL, L., Graux, C., Lewalle, P., Van Gelder, M., Theunissen, K., WILLEMS, E., Emonts, M.-P., De Becker, A., & Beguin, Y. (2015). Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Journal of Hematology and Oncology, 8, 4. doi:10.1186/s13045-014-0098-9

SERVAIS, S., Menten-Dedoyart, C., Beguin, Y., SEIDEL, L., Gothot, A., Daulne, C., WILLEMS, E., Delens, L., Humblet-Baron, S., Hannon, M., & Baron, F. (2015). Impact of Pre-Transplant Anti-T Cell Globulin (ATG) on Immune Recovery after Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation. PLoS ONE, 10 (6), 0130026. doi:10.1371/journal.pone.0130026

BEGUIN, Y., ZACHEE, P., MAERTENS, J., KERRE, T., ORY, A., SEIDEL, L., GRAUX, C., LEWALLE, P., VAN GELDER, M., THEUNISSEN, K., WILLEMS, E., EMONDS, M.-P., DE BECKER, A., & BARON, F. (December 2014). Nonmyeloablative allogeneic hematopoietic cell transplantation following Fludarabine Plus 2 Gy TBI or ATG Plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society. Blood, 124 (21), 542.

JASPERS, A., BARON, F., MAERTENS, J., DE PRIJCK, B., SCHOTS, H., BONNET, C., HAFRAOUI, K., WILLEMS, E., SERVAIS, S., FILLET, G., & BEGUIN, Y. (December 2014). Long-term safety follow-up of a rendomized trial of Darbepoetin Alpha and intravenous iron following autologous hematopoietic cell transplantation. Blood, 124 (21), 3948.

JASPERS, A., Baron, F., WILLEMS, E., Seidel, L., Wiegerinck, E. T., Swinkels, D. W., & BEGUIN, Y. (March 2014). Serum hepcidin following autologous hematopoietic cell transplantation : an illustration of the interplay of iron status, erythropoiesis and inflammation [letter to the editor]. Haematologica, 99 (3), 35-37. doi:10.3324/haematol.2013.100032

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Bonnet, C., & Beguin, Y. (2014). Long-term survival in patients receiving rhEPO following allogeneic hematopoietic cell transplantation. Belgian Journal of Hematology, 14.

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2014). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomized trial. Blood, 124, 33-41. doi:10.1182/blood-2014-01-546333

MOERMANS, C., LECHANTEUR, C., BAUDOUX, E., GIET, O., HENKET, M., SEIDEL, L., LEJEUNE, M., WILLEMS, E., Baron, F., LOUIS, R., & BEGUIN, Y. (2014). Impact of cotransplantation of mesenchymal stem cells on lung function after unrelated allogeneic hematopoietic stem cell transplantation following non-myeloablative conditioning. Transplantation, 98 (3), 348-353. doi:10.1097/TP.0000000000000068

BEGUIN, Y., Maertens, J., DE PRIJCK, B., Schots, R., Seidel, L., BONNET, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., SERVAIS, S., JASPERS, A., FILLET, G., & BARON, F. (2013). Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation : A prospective multicenter randomized trial. American Journal of Hematology, 88, 990-996. doi:10.1002/ajh.23552

JASPERS, A., Baron, F., WILLEMS, E., HAFRAOUI, K., Vanstraelen, G., Bonnet, C., & Beguin, Y. (2013). Erythropoietin therapy after allogeneic hematopoietic cell transplantation : a prospective randomised trial. Belgian Journal of Hematology, 16.

Moermans, C., Poulet, C., HENKET, M., Bonnet, C., WILLEMS, E., Baron, F., Beguin, Y., & Louis, R. (2013). Lung function and airway inflammation monitoring after hematopoietic stem cell transplantation. Respiratory Medicine, 107, 2071-2080. doi:10.1016/j.rmed.2013.10.013

SERVAIS, S., WILLEMS, E., Beguin, Y., & Baron, F. (2013). Allogreffe de cellules souches hématopoïétiques chez le patient âgé : jusqu'à quel âge ? Revue Médicale de Liège, 68 (1), 38-43.

CASTERMANS, E., Hannon, M., Dutrieux, J., Humblet, S., Seidel, L., Cheynier, R., Willems, E., Gothot, A., Vanbellinghen, J.-F., Geenen, V., Sandmaier, B. M., Storb, R., Beguin, Y., & Baron, F. (2011). Thymic recovery after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning is limited to patients younger than 60 years of age. Haematologica, 96(2), 298-306. doi:10.3324/haematol.2010.029702

Servais, S., Willems, E., Beguin, Y., & Baron, F. (2010). Maladie du greffon contre l'hôte chronique : une prise en charge multidisciplinaire. Revue Médicale de Liège, 65, 81-87.

Willems, E.* , Baron, F.* , Seidel, L., Frère, P., Fillet, G., & Beguin, Y. (2010). Comparison of thrombotic microangiopathy after allogeneic hematopoietic cell transplantation with high-dose or nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 689-693. doi:10.1038/bmt.2009.230
* These authors have contributed equally to this work.

Willems, E., Humblet-Baron, S., Dengis, O., Seidel, L., Beguin, Y., & Baron, F. (2010). Elevations of tumor necrosis factor-receptor-1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplantation, 45, 1442-1448. doi:10.1038/bmt.2009.360

Humblet-Baron, S., CASTERMANS, E., Vanbellinghen, J.-F., Hannon, M., Jacobs, N., WILLEMS, E., Ormenese, S., Beguin, Y., & Baron, F. (February 2009). What Is The Role For Regulatory T-Cells After Nonmyeloablative Conditioning? Biology of Blood and Marrow Transplantation, 15 (2), 122-123. doi:10.1016/j.bbmt.2008.12.377

Baron, F., WILLEMS, E., LECHANTEUR, C., BAUDOUX, E., Frere, P., Vanbellinghen, J., Bruck, F., Gothot, A., HAFRAOUI, K., Fillet, G., & Beguin, Y. (2009). Co-transplantation of mesenchymal stem cells might mitigate acute GvHD without abrogating graftversus- tumour alloreactivity after allogeneic transplantation with non-myeloablative conditioning [Paper presentation]. 35th EBMT Annual Meeting.

Beguin, Y., Maertens, J., DE PRIJCK, B., Schots, R., Frère, P., Bonnet, C., HAFRAOUI, K., WILLEMS, E., Vanstraelen, G., LEJEUNE, M., SERVAIS, S., THeunissen, K., Fillet, G., & Baron, F. (2009). A prospective randomized multicenter trial of darbepoetin-alfa and I.V. iron administration after autologous hematopoietic stem cell transplantation [Poster presentation]. 24th General Meeting of the Belgian Hematological Society, Oostende, Belgium.

Castermans, E., Hannon, M., Cheynier, R., Seidel, L., Humblet-Baron, S., WILLEMS, E., Corbier, S., Gothot, A., Geenen, V., Sandmaier, B. M., Storb, R. F., Beguin, Y., & Baron, F. (2009). Thymic Recovery After Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning Might Be Limited to Patients Younger Than 60 Years of Age. Blood, 114 (22), 1149.

Dugauquier, C., Bataille, Y., Willems, E., Frere, P., De Prijck, B., Beguin, Y., & Baron, F. (2009). Toxoplasmore cérébrale compliquant une mini-allogreffe de cellules souches hématopoïétiques du sang périphérique. Revue Médicale de Liège, 64 (7-8), 366-369.

Willems, E.* , Baron, F.* , Baudoux, E., Wanten, N., Seidel, L., Vanbellinghen, J.-F., Herens, C., Gothot, A., Frere, P., Bonnet, C., Hafraoui, K., Vanstraelen, G., Fillet, G., & Beguin, Y. (2009). Non-myeloablative transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a phase II randomized trial. Leukemia, 23 (3), 608-10. doi:10.1038/leu.2008.248
* These authors have contributed equally to this work.

Willems, E., Canivet, J.-L., Ghaye, B., de Leval, L., Radermecker, M., Preiser, J.-C., & Beguin, Y. (2009). Pulmonary veno-occlusive disease in myeloproliferative disorder. European Respiratory Journal, 33 (1), 213-216. doi:10.1183/09031936.00157707

Castermans, E.* , Baron, F.* , Willems, E., Schaaf-Lafontaine, N., Meuris, N., Gothot, A., Vanbellinghen, J.-F., Herens, C., Seidel, L., Geenen, V., Cheynier, R., & Beguin, Y. (2008). Evidence for neo-generation of T cells by the thymus after non-myeloablative conditioning. Haematologica, 93 (2), 240-7. doi:10.3324/haematol.11708
* These authors have contributed equally to this work.

De Prijck, B., Baron, F., Beguin, Y., Bonnet, C., Willems, E., & Fillet, G. (2007). Actualités thérapeutiques en hématologie. Revue Médicale de Liège, 62 (5-6), 384-90.

Frere, P., Baron, F., Bonnet, C., Hafraoui, K., Pereira-Martins, M., Willems, E., Fillet, G., & Beguin, Y. (2006). Infections after allogeneic hematopoietic stem cell transplantation with a nonmyeloablative conditioning regimen. Bone Marrow Transplantation, 37 (4), 411-8. doi:10.1038/sj.bmt.1705255

Vanstraelen, G., Baron, F., Willems, E., Bonnet, C., Hafraoui, K., Frere, P., Fillet, G., & Beguin, Y. (2006). Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response. Experimental Hematology, 34 (7), 841-50. doi:10.1016/j.exphem.2006.04.012

Vanstraelen, G., Frere, P., Ngirabacu, M.-C., Willems, E., Fillet, G., & Beguin, Y. (2006). Pegfilgrastim compared with Filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Experimental Hematology, 34 (3), 382-8. doi:10.1016/j.exphem.2005.11.013

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2006). Nonmyeloablative stem cell transplantation with CD8-depleted or unmalipulated peripheral blood stem cells: a prospective randomized trial [Paper presentation]. 21st General Meeting of the Belgian Hematological Society.

Willems, E., Baron, F., Vanstraelen, G., Frere, P., Fillet, G., & Beguin, Y. (2005). Immunotherapie du cancer par minigreffe de cellules souches hematopoietiques. Revue Médicale Suisse, 1 (30), 1973-7.

WILLEMS, E., CASTERMANS, E., Baron, F., BAUDOUX, E., Wanten, N., Bonnet, C., HAFRAOUI, K., Frère, P., Fillet, G., & Beguin, Y. (2005). Nonmyeloablative stem cell transplantation with CD8-depleted or unmanipulated peripheral blood stem cells: a prospective randomized trial. Blood, 106 (1075).